Publications

Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).

By:
Contributors: Bryan Donnelly, MD, MSc, FRCSC, Dean Ruether, MD FRCSC, Michael Chetner, MD, MSc, FRCSC, FACS, Peter Venner, MD, FRCPC
Can Urol Assoc J. 2011 Dec;5(6):416-21. doi: 10.5489/cuaj.11063.

Abstract

Screening for prostate cancer remains a contentious issue. As with other cancer screening programs, a key feature of the debate is verification of cancerspecific mortality reductions. Unfortunately the present evidence, two systematic reviews and six randomized controlled trials, have reported conflicting results. Furthermore, half of the studies are poor quality and the evidence is clouded by key weaknesses, including poor adherence to screening in the intervention arm or high rates of screening in the control arm. In high quality studies of prostate cancer screening (particularly prostatespecific antigen), in which actual compliance was anticipated in the study design, there is good evidence that prostate cancer mortality is reduced. The numbers needed to screen are at least as good as those of mammography for breast cancer and fecal occult blood testing for colorectal cancer. However, the risks associated with prostate cancer screening are considerable and must be weighed against the advantage of reduced cancerspecific mortality. Adverse events include 70% rate of false positives, important risks associated with prostate biopsy, and the serious consequences of prostate cancer treatment. The best evidence demonstrates prostate cancer screening will reduce prostate cancer mortality. It is time for the debate to move beyond this issue, and begin a well-informed discussion on the remaining complex issues associated with prostate cancer screening and appropriate management.

table

 PubMed

Download PDF

 

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

APCaRI Fall Symposium Oct. 26 to 27, 2018, Banff, Alberta

2018 APCaRI Fall Symposium – Knowledge, Action, Impact

On October 26 – 27, 2018 APCaRI will celebrate its 11th research meeting at the Banff Park Lodge, in Banff, Alberta. Previous fall symposia have had over 60 participants participating in this fun and enriching event, including clinicians, scientists, clinical research personnel, trainees, benefactors and representatives of PCa support groups. Plan on attending the 2018 Fall symposium to discuss and share ideas and enjoy the beautiful Rockies!

Please submit your abstracts to Rume at djebah@ualberta.ca. Please let Rume know as soon as possible if you cannot attend. The APCaRI Fall symposium is generously supported by the Alberta Cancer Foundation and its’ donors

Dates to remember:

Trainee abstract submission deadline is September 10

Registration deadline is September 14

Submit abstracts to djebah@ualberta.ca.

APCaRI Fall symposium site- Banff Park Lodge
Banff Park Lodge

 

 

- Unknown